All In Biotech

Drug Trial Radar · NCT01599286

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Last checked: Nov 20, 2026Latest source record: Feb 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Sep 1, 2012

Primary completion

Apr 30, 2019

Study completion Apr 30, 2020

Sponsor

Lead sponsor
Mendel TuchmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's National Research Institute; Boston Children's Hospital; University Hospitals Cleveland Medical Center; University of California, Los Angeles; Children's Hospital of Philadelphia; Stanford University; Icahn School of Medicine at Mount Sinai; University of Pittsburgh; Children's Hospital Colorado
First posted
May 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 week, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this drug trial is to determine whether the treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG, Carglumic acid) in propionic acidemia (PA), methylmalonic acidemia (MMA), late-onset CPS1 deficiency (CPSD) and late-onset Ornithine transcarbamylase deficiency (OTCD) accelerates the resolution of hyperammonemia efficiently and safely. The primary goal is to determine if the study drug (NCG) efficiently reduces ammonia levels following a hyperammonemia episode(s). Secondly, the investigators want to know if treatment with this study drug (NCG) efficiently improves neurologic function, reduces plasma glutamine levels and lessens the duration of hospitalization after each episode of hyperammonemia.

Conditions

  • Propionic Acidemia, Type I and/or Type II
  • Methylmalonic Acidemia
  • Carbamoyl-Phosphate Synthase I Deficiency Disease
  • Ornithine Carbamoyltransferase Deficiency

Interventions

  • CarbagluDrug

    Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG) The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration. The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.

  • PlaceboDrug

    Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge)Time frame: Average of all measurements of hyperammonemia, for up to 7 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Lucile Packard Children's Hospital at Stanford

    Palo Alto, California

  • The Children's Hospital of Colorado

    Aurora, Colorado

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Hospital Boston

    Boston, Massachusetts

  • Mount Sinai School of Medicine

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.